tetano
Editor, Senior Moderator
Antivir Ther
. 2025 Dec;30(6):13596535251405300.
doi: 10.1177/13596535251405300. Epub 2025 Dec 8. Evaluation of combining the PDX analogue AN-137B with oseltamivir in a mouse model of severe influenza A (H1N1) infection
Yacine Abed[SUP] 1 [/SUP], Chantal Rhéaume[SUP] 1 [/SUP], Julie Carbonneau[SUP] 1 [/SUP], Nicolas Fortin[SUP] 1 [/SUP], René Maltais[SUP] 2 [/SUP], André Marette[SUP] 2 [/SUP], Donald Poirier[SUP] 2 [/SUP], Guy Boivin[SUP] 1 [/SUP]
Affiliations
Severe influenza infections involve an exacerbation of the pro-inflammatory response, which is influenced by both viral and host factors. Protectins PD1 and PDX previously demonstrated anti-influenza activity as well as anti-inflammatory properties. We recently reported that the combination of AN-137B, a molecular analogue of PDX, with oseltamivir or baloxavir provided synergism/additive effects against influenza, in vitro. Herein, we investigated potential benefits of the AN-137B-oseltamivir combination in mice infected with influenza A/Puerto Rico/8/1934 (H1N1) virus. Untreated animals and those that received single oseltamivir or AN-137B treatment showed mortality rates of 80%, 100% and 100%, respectively, whereas only 40% of mice that received the oseltamivir-AN-137B combination had to be euthanized. Body weight loss was also lower in the group of the combination. In the latter group, the mean lung viral titre (LVT), as determined by plaque assay (2.53 ± 0.63 × 10[SUP]5[/SUP] PFU/mL) and by qRT-PCR (2.39 ± 1.3 × 10[SUP]8[/SUP] copies/mL), was significantly lower than that of the untreated group (4.76 ± 0.9 × 10[SUP]5[/SUP] PFU/mL and 3.75 ± 0.86 × 10[SUP]8[/SUP] copies/mL (p < .05), contrasting with LVTs of animals that received single therapies. These in vivo results reinforce the potential of AN-137B when combined to a potent anti-influenza agent against severe influenza.
Keywords: AN-137B; combination therapy; influenza; oseltamivir; protectin.
. 2025 Dec;30(6):13596535251405300.
doi: 10.1177/13596535251405300. Epub 2025 Dec 8. Evaluation of combining the PDX analogue AN-137B with oseltamivir in a mouse model of severe influenza A (H1N1) infection
Yacine Abed[SUP] 1 [/SUP], Chantal Rhéaume[SUP] 1 [/SUP], Julie Carbonneau[SUP] 1 [/SUP], Nicolas Fortin[SUP] 1 [/SUP], René Maltais[SUP] 2 [/SUP], André Marette[SUP] 2 [/SUP], Donald Poirier[SUP] 2 [/SUP], Guy Boivin[SUP] 1 [/SUP]
Affiliations
- PMID: 41361734
- DOI: 10.1177/13596535251405300
Severe influenza infections involve an exacerbation of the pro-inflammatory response, which is influenced by both viral and host factors. Protectins PD1 and PDX previously demonstrated anti-influenza activity as well as anti-inflammatory properties. We recently reported that the combination of AN-137B, a molecular analogue of PDX, with oseltamivir or baloxavir provided synergism/additive effects against influenza, in vitro. Herein, we investigated potential benefits of the AN-137B-oseltamivir combination in mice infected with influenza A/Puerto Rico/8/1934 (H1N1) virus. Untreated animals and those that received single oseltamivir or AN-137B treatment showed mortality rates of 80%, 100% and 100%, respectively, whereas only 40% of mice that received the oseltamivir-AN-137B combination had to be euthanized. Body weight loss was also lower in the group of the combination. In the latter group, the mean lung viral titre (LVT), as determined by plaque assay (2.53 ± 0.63 × 10[SUP]5[/SUP] PFU/mL) and by qRT-PCR (2.39 ± 1.3 × 10[SUP]8[/SUP] copies/mL), was significantly lower than that of the untreated group (4.76 ± 0.9 × 10[SUP]5[/SUP] PFU/mL and 3.75 ± 0.86 × 10[SUP]8[/SUP] copies/mL (p < .05), contrasting with LVTs of animals that received single therapies. These in vivo results reinforce the potential of AN-137B when combined to a potent anti-influenza agent against severe influenza.
Keywords: AN-137B; combination therapy; influenza; oseltamivir; protectin.